A cell-permeable peptide inhibits hepatitis C virus replication by sequestering IRES transacting factors.
Ontology highlight
ABSTRACT: Hepatitis C virus (HCV) infection frequently leads to chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma. There is no effective therapy or vaccine available to HCV-infected patients other than interferon-ribavarin combination, which is effective in a relatively small percentage of infected patients. Our previous results have shown that a synthetic peptide (LAP) corresponding to the N-terminal 18 amino acids of the Lupus autoantigen (La) was a potent inhibitor of HCV IRES-mediated translation. We demonstrate here that LAP efficiently blocks HCV replication of infectious JFH1 virus in cell culture. Our data suggest that LAP forms complexes with IRES-transacting factors (ITAFs) PTB and PCBP2. LAP-mediated inhibition of HCV IRES-mediated translation in vitro could be fully rescue
SUBMITTER: Fontanes V
PROVIDER: S-EPMC2767405 | biostudies-literature | 2009 Nov
REPOSITORIES: biostudies-literature
ACCESS DATA